OnKure Therapeutics, Inc.: Venrock Healthcare Capital Partners III, L.P. discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Venrock Healthcare Capital Partners III, L.P. disclosed a stake of more than 5% in OnKure Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0001231919-26-001621). The filing signals the venture firm's sizable position in the clinical-stage biotech, though the disclosure did not specify the exact share count or percentage held. A Schedule 13G is typically used by passive investors, suggesting Venrock is not seeking control of the company. Investors will watch for further detail on the position's size and any subsequent 13G amendments, as well as OnKure's clinical progress.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
OnKure Therapeutics, Inc., Venrock Healthcare Capital Partners III, L.P.